BioInformant

Your Global Leader in Stem Cell Market Research

Home » Cell Therapy » Page 6

Eli Lilly Commits Up to $2.4B to Orna Therapeutics in Major Bet on In Vivo CAR-T

By Leave a Comment

In news announced yesterday (February 9, 2026), Eli Lilly revealed plans to acquire Orna Therapeutics for up to $2.4 billion, a truly staggering price tag. The move marks a decisive step toward the next generation of cell therapy: programming immune cells directly inside the patient rather than manufacturing them outside the body.

Importantly, this transaction is not centered on a single pipeline candidate, but on securing a platform technology that could reshape how CAR-T and other immune-reset strategies are developed and delivered across autoimmune disease and beyond. [Read more…]

Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering

By Leave a Comment

Across 2025, a striking trend has emerged in biotechnology. Major pharmaceutical companies are racing to acquire in vivo cell engineering platforms, signaling that reprogramming cells inside the body has moved from speculative science to strategic priority.

In just a few months, the field has transformed. AstraZeneca, AbbVie, Gilead’s Kite Pharma, and Bristol Myers Squibb have all made acquisitions designed to accelerate their capabilities in in vivo cell therapy. Each deal highlights the growing importance of technologies that can directly engineer immune cells without removing them from the body. [Read more…]

Ways to Curb the Sky-high Costs of CAR-T Cell Therapy

By Leave a Comment

CAR-T therapy has revolutionized cancer treatment, offering a personalized approach that uses genetically modified T cells to target and destroy cancer cells. However, this breakthrough treatment comes at a steep price. In the U.S., CAR-T therapies are priced between $300,000 and $600,000, and when factoring in the costs of treating adverse reactions and hospital stays, the total expenditure can exceed $1,000,000. The high cost makes it inaccessible for many patients and poses a challenge for healthcare systems worldwide.

To address this issue, experts and industry leaders have proposed several strategies to reduce the cost of CAR-T therapy while maintaining its efficacy and accessibility. [Read more…]

CAR-T Market Leaders in 2026: Leaders, Innovators, and Game-Changing Tech

By Leave a Comment

Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the landscape of oncology, offering personalized cellular solutions for hematologic malignancies and expanding into solid tumors and autoimmune disorders. By engineering a patient’s own T-cells to recognize and destroy cancer cells, CAR-T therapies provide unprecedented efficacy, often in patient populations with limited treatment options.

The global CAR-T market has grown substantially in recent years, climbing to 13 approvals worldwide. Seven of these therapies have been approved by the U.S. FDA, with subsequent approvals in other major healthcare markets. These therapies include Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, and Aucatzyl. Beyond the U.S., four CAR-T therapies (Relma-cel, Fucaso, Yuanruida, and Zever-cel) have been approved by China’s National Medical Products Administration (NMPA), while two therapies, NexCAR19 and Qartemi, have received approval from India’s Central Drugs Standard Control Organisation (CDSCO). [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0